Company intelligence / Profile preview

3Sixteen

Lafayette, California, United States3sixteen.com ↗

Ownership: Private
Development stage: Commercial

Overview

TenSixteen Bio leverages somatic mosaicism—especially clonal hematopoiesis of indeterminate potential—to discover new drug targets, develop precision medicine approaches, and build infrastructure to identify patients at risk or likely to respond to future therapies. The company has raised $40M in funding but has not yet announced any clinical results or advanced candidates into human trials.

Therapeutic areas: OncologyImmunologyOtherCardiovascularInfectious Diseases
Industry: Biotech

Beyond the preview

Go deeper on 3Sixteen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3Sixteen.

Explore the full profile